Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05823974 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,275
- Enrollment target
NCT05823974: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT05823974 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,275 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2025% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05823974, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,275 participants
- Enrollment target
Study Summary
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
Primary Outcome
Assessed solicited administration site events included pain, redness (Erythema), swelling, lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.
Interventions
- BIOLOGICAL F2C22C/DL001Z
- BIOLOGICAL F2B22A/DL001Z
- BIOLOGICAL F2B22B/DL001Z
- BIOLOGICAL F2B22C/DL001Z
- BIOLOGICAL F2B22D/DL001Z
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,275 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2024-12-18 |
| Phase | Phase 1 |
What the finished NCT05823974 record still lists
NCT05823974 is an interventional study that assigns participants to a tested intervention. Its 1,275 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (2025% higher).
The record links to 0 conditions, and to 5 interventions - of which F2C22C/DL001Z is the first listed.
NCT05823974 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05823974 about?
NCT05823974 is a clinical study titled "A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults". The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
What is the current status of trial NCT05823974?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,275 participants. The study started on 2023-04-27. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT05823974?
The interventions under investigation include: F2C22C/DL001Z (BIOLOGICAL), F2B22A/DL001Z (BIOLOGICAL), F2B22B/DL001Z (BIOLOGICAL), F2B22C/DL001Z (BIOLOGICAL), F2B22D/DL001Z (BIOLOGICAL).
Who is sponsoring clinical trial NCT05823974?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05823974's enrollment target sits among peer trials
1,275 5th of 2000 higher than 1,996 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI